WHO Hubris

From misappropriating IP to taxation without representation and poor pandemic management, what’s to like about the WHO? My recent piece in the Financial Post, here.

Reality Check

Here is the second of two papers I’ve written on Canada’s dysfunctional drug pricing system. This one takes a wider view of the intellectual deception and myths that sustain our self-defeating approach to the pharmaceutical industry.

The Kindest Cut

In the first of two papers for the Macdonald-Laurier institute examining the history and impact of drug price controls in Canada, I argue for doing away with the Patented Medicine Prices Review Board and leading nations toward a more equitable sharing of the costs of pharmaceutical development. The first paper is here, and the second will be published shortly.